紫杉醇联合卡铂化疗对卵巢癌VEGF及肿瘤标志物表达的影响

doi:10.16352/j.issn.1001-6325.2023.12.1861

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (12): 1861-1865.doi: 10.16352/j.issn.1001-6325.2023.12.1861

紫杉醇联合卡铂化疗对卵巢癌VEGF及肿瘤标志物表达的影响

谭树芬^1*, 杨谢兰¹, 杨琳琳¹, 李树清²

1.昆明医科大学第三附属医院妇科,云南昆明 650118;
2.昆明医科大学基础医学院,云南昆明 650050

收稿日期:2022-11-29 修回日期:2023-05-04 出版日期:2023-12-05 发布日期:2023-11-29
通讯作者: ^* shufen591@hotmail.com

Effects of paclitaxel combined with carboplatin on expression of VEGF and tumor markers in ovarian cancer

TAN Shufen^1*, YANG Xielan¹, YANG Linlin¹, LI Shuqing²

1. Department of Gynecology, the Third Affiliated Hospital of Kunming Medical University,Kunming 650118;
2. School of Basic Medical Sciences, Kunming Medical University, Kunming 650500,China

Received:2022-11-29 Revised:2023-05-04 Online:2023-12-05 Published:2023-11-29
Contact: ^* shufen591@hotmail.com

摘要/Abstract

摘要： 目的探讨紫杉醇与卡铂联合化疗对卵巢癌(OC)患者血细胞相关指标、血管内皮生长因子(VEGF) 及肿瘤标志物的影响。方法 OC患者联合化疗(CC)组和卵巢良性肿瘤对照(control)组,各组50例。HE染色观察OC卵巢细胞病理改变,免疫组化染色(IHC)观察VEGF表达;流式细胞术(FC)检测血细胞数量;电化学发光法(ECL)检血清糖类抗原125(CA125) 和人附睾蛋白4(HE4)水平。结果与对照组相比,OC卵巢织织结构紊乱,细胞异型明显;VEGF表达明显增强,血小板(PLT)计数、CA125和HE4水平显著升高(P＜0.01)。但化疗后CC组卵巢组织可见坏死细胞、VEGF表达减弱、PLT计数、CA125和HE4水平较对照组显著降低(P＜0.01)。结论联合化疗对OC患者VEGF表达以及CA125、HE4水平具有调节作用。

关键词: 卵巢癌, 联合化疗, 血细胞, 血管内皮生长因子, 肿瘤标记物

Abstract: Objective To explore the effect of paclitaxel with carboplatin combined chemotherapy on hemocyte related indexes,vascular endothelial growth factor (VEGF) and tumor markers in ovarian cancer (OC) patients. Methods OC patients combined chemotherapy (CC) group and ovarian benign tumor control group with 50 cases in each. The pathological changes in the ovarian cells were observed by HE staining and the expression of VEGF was observed by immunohistochemical staining (IHC).Blood cell was counted by flow cytometry (FC). Serum carbohydrate antigen 125 (CA125) and human epididymal protein 4 (HE4) were measured by electrochemical luminescence (ECL). Results Compared with control group, the ovarian tissue structure was disordered and the cell atypia was obvious in OC.VEGF expression was significantly enhanced. Platelet count (PLT), CA125 and HE4 were significantly increased (P＜0.01). However,necrotic cells were observed in ovarian tissue of CC group.VEGF expression was inhibited.PLT count and the level of CA125 and HE4 were significantly lower than those of control group after chemotherapy(P＜0.01). Conclusions Combined chemotherapy may regulate the level of VEGF, CA125 and HE4 in OC patients.

Key words: ovarian cancer, combined chemotherapy, blood cells, VEGF, tumor marker

中图分类号:

R730.231

谭树芬, 杨谢兰, 杨琳琳, 李树清. 紫杉醇联合卡铂化疗对卵巢癌VEGF及肿瘤标志物表达的影响[J]. 基础医学与临床, 2023, 43(12): 1861-1865.

TAN Shufen, YANG Xielan, YANG Linlin, LI Shuqing. Effects of paclitaxel combined with carboplatin on expression of VEGF and tumor markers in ovarian cancer[J]. Basic & Clinical Medicine, 2023, 43(12): 1861-1865.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.12.1861

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I12/1861

参考文献 16

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics[J].CA Cancer J Clin,2018, 68:7-30.
[2]	Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia,Canada, Denmark, Norway, Sweden, and the UK,1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data[J]. Lancet, 2011,377:127-138.
[3]	Teliga-Czajkowska J, Sienko J, Jalinik K,et al. Plasminogen activator inhibitor type1 in blood at onset of chemotherapy unfavorably affects survival in primary ovarian cancer[J]. Adv Exp Med Biol,2019,5: 47-54.
[4]	Yang J, Jin Y, Cheng S,et al.Clinical signifcance for combined coagulation indexes in epithelial ovarian cancer prognosis[J]. J Ovarian Res,2021,14:106-116.
[5]	Cho MS,Li J,Gonzalez-Delgado R,et al. The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer[J]. Blood Adv, 2021, 5:1947-1951.
[6]	Falanga A, Marchetti M, Russo L.The mechanisms of cancer-associated thrombosis[J]. Thromb Res, 2015,135:S8-S11.
[7]	Jaiswal RK, Varshney AK, Yadava PK. Diversity and functional evolution of the plasminogen activator system[J]. Biomed Pharmacother,2018,98:886-898.
[8]	Haemmerle M,Taylor ML,Gutschner T,et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling[J]. Nat Commun,2017,8:310.doi:10.1038/s41467-017-00411-z.
[9]	Li W, Tang Y, Song Y, et al. Prognostic role of pretreatment plasma D-Dimer in patients with solid tumors: a systematic review and meta-analysis[J]. Cell Physiol Biochem, 2018, 45: 1663-1676.
[10]	Lal I, Dittus K,Holmes CE.Platelets, coagulation and fibrinolysis in breast cancer progression[J].Breast Cancer Res,2013, 15:207-219.
[11]	吴梦,娄鉴芳,黄珮珺,等. 卵巢癌细胞通过p38 MAPK通路促进CD8+调节T细胞的生成[J]. 基础医学与临床, 2016, 36: 167-172.
[12]	Bortot B, Mangogna A, Peacock B,et al.Platelet activation in ovarian cancer ascites: assessment of GPIIb/IIIa and PF4 in small extracellular vesicles by nano-flow cytometry analysis[J]. Cancers, 2022, 14:4100 doi:10.3390/cancers14174100.
[13]	李少儒,秦海霞,刘珊珊,等.miR-493-5p抑制人卵巢癌细胞系SKOV3增殖和迁移[J].基础医学与临床,2021,41:1749-1755.
[14]	Collinson FJ, Seligmann J, Perren TJ.Ovarian cancer: advances in first-line treatment strategies with a particular focus on antiangiogenic agents[J].Current oncol Rep,2012,14:509-518.
[15]	Rubio-Jurado B, Balderas-Penal M, Garcia-Lunae E, et al. Obesity, thrombotic risk, and inflammation in cancer[J]. Adv Clin Chem, 2018, 85: 71-89.
[16]	Reiser E,Pils D,Grimm C,et al.Defining models to classify between benign and malignant adnexal masses using routine laboratoryparameters[J].Cancers, 2022,14:3210. doi:10.3390/cancers14133210.

紫杉醇联合卡铂化疗对卵巢癌VEGF及肿瘤标志物表达的影响

Effects of paclitaxel combined with carboplatin on expression of VEGF and tumor markers in ovarian cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 16

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄洁, 李润博, 郭建新, 韩健. DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响[J]. 基础医学与临床, 2023, 43(8): 1247-1253.
[2]	冷海娜, 张艳, 王晓栋, 张学友, 李洪利. miR-767-5p通过调控TBL1XR1蛋白表达抑制人卵巢癌细胞系侵袭[J]. 基础医学与临床, 2023, 43(3): 408-414.
[3]	骞立刚, 孙博, 于泊, 陈康, 马铮, 陈涛平, 王云飞. 丹酚酸B减轻骨关节炎模型大鼠软骨组织损伤[J]. 基础医学与临床, 2023, 43(1): 159-164.
[4]	王娟, 张晓燕, 朱爱华, 于宏波, 范新丹, 汤春辉, 姚秀芳. Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关[J]. 基础医学与临床, 2022, 42(9): 1391-1399.
[5]	韩甜甜, 尹婕, 曾靖, 金滢, 李艳, 潘凌亚. 稳定表达CDC50A的卵巢癌细胞株的建立及鉴定[J]. 基础医学与临床, 2022, 42(6): 896-901.
[6]	尹婕, 潘凌亚, 温仪萍, 黄虹, 曾靖, 李晓莹, 韩甜甜, 金滢, 李艳. 人上皮性卵巢癌细胞系侧群细胞的肿瘤干细胞样细胞生物学特性及膜蛋白差异表达的鉴定[J]. 基础医学与临床, 2022, 42(2): 221-227.
[7]	董辉, 王婷婷, 马晓红, 马盛宗, 丁永慧. 卵巢癌组织中差异lncRNAs的筛选及其lncRNA ZEB2-AS1的表达分析[J]. 基础医学与临床, 2022, 42(11): 1675-1680.
[8]	王海燕, 黄明全, 潘广锐, 汪贵林, 梁斌, 权毅. 低氧微环境促进人乳腺癌细胞系MCF-7的侵袭和增殖[J]. 基础医学与临床, 2021, 41(4): 539-544.
[9]	董玲玲, 高云, 牛国宇. 结缔组织生长因子促进人卵巢癌细胞系SKOV3增殖与迁移[J]. 基础医学与临床, 2021, 41(2): 193-196.
[10]	李少儒, 秦海霞, 刘珊珊, 侯瑞杰. miR-493-5p抑制人卵巢癌细胞系SKOV3增殖和迁移[J]. 基础医学与临床, 2021, 41(12): 1749-1755.
[11]	黄博, 程苾恒, 解美婷, 刘珊汕, 魏敏. FOXM1促进子宫内膜癌细胞系HEC-1B增殖、迁移和侵袭[J]. 基础医学与临床, 2021, 41(12): 1780-1785.
[12]	董莉丽, 冯磊, 杨然, 李松, 饶玉梅. 过表达内质网蛋白29抑制人卵巢癌细胞系OVCAR3侵袭和迁移[J]. 基础医学与临床, 2021, 41(10): 1434-1439.
[13]	高静, 周家奇. 降低脂筏内integrin β1减轻HPS大鼠血清诱导PMVECs增殖和迁移[J]. 基础医学与临床, 2021, 41(10): 1417-1422.
[14]	于婧王凤琴姚文娟吴冬梅刘大鹏. 甲状腺乳头状癌BRAFV600E基因突变对VEGF和MMP-9表达的影响?[J]. , 2019, 39(11): 1578-1582.
[15]	刘南京李婷赵燕郝燕妮吴小候罗春丽. miR-29c促进前列腺癌PC3细胞凋亡[J]. 基础医学与临床, 2017, 37(12): 1706-1711.